SCHEMBL4920883

SCHEMBL4920883

Cc1[nH]c(C(F)(F)F)c(C(=O)OC(C)(C)C)c1-c1ccc(C#N)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.38
ALDH1A1 P00352 4/20 0.38
POLB P06746 2/20 0.38
GYS1 P13807 1/20 0.37
GPR119 Q8TDV5 1/20 0.36
AR P10275 1/20 0.36
KIF11 P52732 1/20 0.35
LMNA P02545 2/20 0.35
MEN1 O00255 3/20 0.34
GAA P10253 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
PSD A5PKW4 1/20 0.34
MAPT P10636 2/20 0.34
HTT P42858 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34
ESR1 P03372 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4922469 0.88 KMT2A (0.51) KMT2AALDH1A1POLBGYS1AR
SCHEMBL5361685 0.87 KMT2A (0.51) KMT2AALDH1A1POLBGPR119AR
SCHEMBL4918581 0.84 KMT2A (0.40) KMT2AALDH1A1POLBGPR119AR
SCHEMBL5355574 0.84 GYS1 (0.40) KMT2AALDH1A1POLBGYS1AR
SCHEMBL4913965 0.83 KMT2A (0.39) KMT2AALDH1A1POLBGPR119AR
SCHEMBL5351989 0.81 ALDH1A1 (0.43) KMT2AALDH1A1POLBARLMNA
SCHEMBL6465912 0.73 CNR2 (0.50) KMT2AALDH1A1ARLMNAMEN1
SCHEMBL4919275 0.73 HTT (0.49) KMT2AALDH1A1POLBGPR119KIF11
SCHEMBL4914072 0.73 KDM1A (0.38) GPR119ARKIF11GABRA1GABRG2
SCHEMBL6465908 0.72 ALDH1A1 (0.71) KMT2AALDH1A1POLBARLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176906-A1 Substituted Pyrrole Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 US disclosed
US-20080176906-A1 Substituted Pyrrole Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 US disclosed
US-20080176906-A1 Substituted Pyrrole Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 US disclosed
WO-2007145349-A2 SUBSTITUTED PYRROLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-12-21 WO disclosed
WO-2007145349-A2 SUBSTITUTED PYRROLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-12-21 WO disclosed
EP-1824841-A1 SUBSTITUTED PYRROLE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2007-08-29 EP disclosed
WO-2006064944-A1 SUBSTITUTED PYRROLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176906-A1 Substituted Pyrrole Derivative AR, NR5A1, MC2R KMT2A 1736/4885ALDH1A1 408/4885POLB 3551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.